Phase
Condition
Rheumatoid Arthritis
Joint Injuries
Arthritis And Arthritic Pain
Treatment
Baricitinib
Sarilumab
Hydroxychloroquine
Clinical Study ID
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
INCLUSION CRITERIA:
Diagnosed rheumatoid arthritis (RA) with 4 of 7 American College of Rheumatologycriteria
Morning stiffness for at least 1 hour for at least 6 weeks
Swelling of 3 or more joints for at least 6 weeks
Swelling of wrist, metacarpophalangeal (MCP), or proximal interphalangealjoints for 6 or more weeks
Symmetric joint swelling
Hand x-rays with erosions or bony decalcifications
RA nodules
Rheumatoid factor (RF) positive
>19 yrs old at RA diagnosis
Active disease with at least 1 swollen joint
Starting new DMARD medication(s) (abatacept, adalimumab, azathioprine, barcitinib,certolizumab, etanercept, golimumab, hydroxychloroquine, infliximab, leflunomide,methotrexate, minocycline, rituximab, sarilumab, sulfasalazine, tofacitinib)
If on other DMARDS, must be on stable dose for ≥ 6 wks
If on glucocorticoids, must be on stable dose for 2 wks (< 10mg of Prednisone/day orequivalent)
Able to adhere to study visit schedule: enrollment (8 wks & 16 wks +/- 2 wks)
Hemoglobin (Hgb) > 9g/dl
Platelets >100
Creatinine <1.6
Aspartate transferase (AST) or alanine aminotransferase (ALT) at or below 1.2 xupper limit
Albumin up to 1.0 g/dL below lower limit of normal
Exclusion
EXCLUSION CRITERIA:
Pregnant or breastfeeding women
Men and women of child bearing potential unwilling to practice effective method ofcontraception
Study Design
Study Description
Connect with a study center
University of Nebraska Medical Center
Omaha, Nebraska 68198
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.